Incyte
INCY
$56.52
Share price
-0.94%
Change (1 day)
-14.63%
Change (1 year)
Categories
Incyte (INCY) - Cash on Hand
Cash on Hand as of March 2024 : $3.85 B
According to Incyte's latest financial reports the company has $3.85 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Incyte - Cash on Hand chart (from 2001 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $3.65 B | 12.88% |
| 2022-12-31 | $3.23 B | 37.93% |
| 2021-12-31 | $2.34 B | 30.36% |
| 2020-12-31 | $1.80 B | -14.93% |
| 2019-12-31 | $2.11 B | 47.22% |
| 2018-12-31 | $1.43 B | 22.97% |
| 2017-12-31 | $1.16 B | 44.66% |
| 2016-12-31 | $0.80 B | 14.24% |
| 2015-12-31 | $0.70 B | 17.91% |
| 2014-12-31 | $0.60 B | 17.93% |
| 2013-12-31 | $0.50 B | 122.84% |
| 2012-12-31 | $0.22 B | -17.72% |
| 2011-12-31 | $0.27 B | -34.56% |
| 2010-12-31 | $0.42 B | -9.83% |
| 2009-12-31 | $0.47 B | 137.56% |
| 2008-12-31 | $0.19 B | -22.78% |
| 2007-12-31 | $0.25 B | -19.51% |
| 2006-12-31 | $0.31 B | -7.65% |
| 2005-12-31 | $0.34 B | -26.57% |
| 2004-12-31 | $0.46 B | 59.89% |
| 2003-12-31 | $0.29 B | -31.52% |
| 2002-12-31 | $0.42 B | -15.53% |
| 2001-12-31 | $0.50 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $9.69 B | 151.75% | 🇨🇭 Switzerland |
 Pfizer PFE | $12.69 B | 229.55% | 🇺🇸 USA |
 Eli Lilly LLY | $2.58 B | -32.84% | 🇺🇸 USA |
 Amgen AMGN | $10.94 B | 184.21% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | $0.17 B | -95.58% | 🇺🇸 USA |
 Geron GERN | $0.33 B | -91.33% | 🇺🇸 USA |
 CTI BioPharma
CTIC | $59.01 M | -98.47% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $77.39 M | -97.99% | 🇺🇸 USA |
 Ardelyx ARDX | $0.18 B | -95.21% | 🇺🇸 USA |